Neuroform Atlas Stent System
Stryker Neurovascular · Decision date May 16, 2019
What did the FDA approve?
The FDA approved the Neuroform Atlas Stent System for use with neurovascular embolization coils in the anterior circulation of the neurovasculature. The approval covers endovascular treatment of patients 18 years or older with saccular wide-necked intracranial aneurysms, defined as neck width of 4 mm or greater or a dome-to-neck ratio below 2.
The device is limited to aneurysms arising from a parent vessel with a diameter of at least 2.0 mm and no more than 4.5 mm. The decision date is May 16, 2019, and the applicant is Stryker Neurovascular. The source statement describes the approved scope but does not provide independent proof of safety or clinical effectiveness.
FDA approval order statement
Approved for use with neurovascular embolization coils in the anterior circulation of the neurovasculature for the endovascular treatment of patients greater or equal to 18 years of age with saccular wide-necked (neck width greater or equal to 4 mm or a dome-to-neck ratio of < 2) intracranial aneurysms arising from a parent vessel with a diameter of greater or equal to 2.0 mm and less than or equal to 4.5 mm.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- May 16, 2019
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P180031
- Regulatory pathway
- Premarket approval application
- Applicant
- Stryker Neurovascular
- Product code
- QCA
- Decision code
- APPR
- Decision date
- May 16, 2019
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Intracranial coil-assist stent.
- Applicant
- Stryker Neurovascular
- Product code
- QCA
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P180031 received
Application receipt date recorded by FDA.
P180031 · FDA decision
APPR
P180031/S012 · Related supplement
Neuroform Atlas Stent System
Timeline entries are records held by MedtechLedger for P180031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Neuroform Atlas Stent SystemP180031/S012 | Stryker Neurovascular | PMA supplement | Oct 24, 2026 | FDA |
Explore the linked device profile
Other records with product code QCA
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Microvention, Inc. | PMA supplement | Sep 16, 2026 | FDA | |
| Microvention, Inc. | PMA approval | May 30, 2018 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Stryker Neurovascular
- Headquarters
- Not reported
- Brand website
- stryker.com
- FDA applicant address
- 47900 Bayside Pkwy., Fremont, CA, 94538
Sources and methodology
- Original FDA record: P180031
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

